There’s been exciting progress on a new approach treating Nemaline Myopathy (NM), the rare muscle disorder that causes weakness and low muscle tone. While researchers have identified twelve different faulty genes that cause NM and prevent muscles from working properly (ACTA1, NEB, TPM2, TPM3, KBTBD13, CFL2, KLHL40, KLHL41, LMOD3, MYPN, TNNT1, and TNNT3, with the…
Read More
Living with Nemaline Myopathy (NM)? Join the global fight for treatments & therapies! Register with the CMDIR and unlock access to clinical trials, resources, and a supportive community. Be the hero of your story.
Read MoreRecently, the AFBS team had the privilege of attending the World Muscle Society Congress in South Carolina, where AFBS’ Scientific Director, Gus Dziewczapolski, AFBS’ Program Manager, Stacy Cossette, and AFBS’ PCORI Program Coordinator, Sarah Foye, participated in this enlightening event. Pictured Above: AFBS Scientific Director, Gus Dziewczapolski, AFBS Scientific Advisory Dr. Alan Beggs, AFBS Program Director Stacy…
Read More
Brigham and Women’s Hospital’s Spring Issue highlights a $1.2 million grant from AFBS and the Machado family, supporting research for rare muscle disorder nemaline myopathy.
Read MoreIn the latest webinar of the series, “Amplifying the NM Community’s Voice”, we were joined by peers and Nemaline Myopathy (NM) experts to better understand challenges and opportunities related to NM, identifying priorities and ultimately advancing research. Watch the full webinar to hear all the insight, announcements and feedback from peers and clinicians: NM Natural…
Read More
In the latest webinar of the series, “Amplifying the NM Community’s Voice”, we were joined by three expert Nemaline Myopathy (NM) researchers from across North America who shared thorough updates on models (or tools) that have been created for use in gene-specific NM research.
Read More
AFBS is investing in research to bring us closer to treatments for Nemaline Myopathy (NM). Dr. Dowling at SickKids Hospotal is exploring the application of CRISPR/Cas9 to NM therapeutics, and we’re funding his latest research.
Read More